1887

Abstract

We have evaluated the contribution of the 1,3---glucan (BG) assay for the screening of invasive fungal infections (IFIs) in patients with haematological malignancies. Serum samples from patients at risk of IFI were collected twice a week and retrospectively tested using the BG assay. BG screening was performed on 1143 samples from 91 patients during 104 anticancer treatment cycles. Proven and probable cases of IFI occurred in 9 (8.7 %) treatment cycles. Depending on the criterion of positivity used (1× >60 pg ml, 1× >80 pg ml, 2× >60 pg ml or 2× >80 pg ml) the sensitivity and specificity were 89, 89, 67 and 44 %, and 20, 48, 33 and 56 %, respectively. Although the test was marked as positive in 82, 68, 54 and 45 % of all the treatment cycles, in the majority of cases, these positivities were probably false. The major limit of the BG test was an extremely low positive predictive value (10 to 12 %). We have analysed mucositis, candida colonization, bacteraemia, use of antimicrobials, erythrocyte and thrombocyte filtered blood products, collecting tubes or sampling via venous catheters. Even though no factor is a major source of BG, it could at least partially influence BG assay performance. Thus, BG detection has a limited usefulness as a screening method for IFIs in patients with haematological malignancies.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.019299-0
2010-09-01
2019-12-12
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/9/1016.html?itemId=/content/journal/jmm/10.1099/jmm.0.019299-0&mimeType=html&fmt=ahah

References

  1. Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E. & other authors ( 2002; ). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34, 7–14.[CrossRef]
    [Google Scholar]
  2. De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O. & other authors ( 2008; ). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46, 1813–1821.[CrossRef]
    [Google Scholar]
  3. Desmet, S., Van Wijngaerden, E., Maertens, J., Verhaegen, J., Verbeken, E., De Munter, P., Meersseman, W., Van Meensel, B., Van Eldere, J. & other authors ( 2009; ). Serum (1–3)-β-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 47, 3871–3874.[CrossRef]
    [Google Scholar]
  4. Digby, J., Kalbfleisch, J., Glenn, A., Larsen, A., Browder, W. & Williams, D. ( 2003; ). Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10, 882–885.
    [Google Scholar]
  5. Ellis, M., Al-Ramadi, B., Finkelman, M., Hedstrom, U., Kristensen, J., Ali-Zadeh, H. & Klingspor, L. ( 2008; ). Assessment of the clinical utility of serial β-d-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57, 287–295.[CrossRef]
    [Google Scholar]
  6. Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S. & Bearden, D. T. ( 2006; ). Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43, 25–31.[CrossRef]
    [Google Scholar]
  7. Hachem, R. Y., Kontoyiannis, D. P., Chemaly, R. F., Jiang, Y., Reitzel, R. & Raad, I. ( 2009; ). Utility of galactomannan enzyme immunoassay and (1,3) β-d-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 47, 129–133.[CrossRef]
    [Google Scholar]
  8. Kedzierska, A., Kochan, P., Pietrzyk, A. & Kedzierska, J. ( 2007; ). Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1→3)-β-d-glucan antigens. Eur J Clin Microbiol Infect Dis 26, 755–766.[CrossRef]
    [Google Scholar]
  9. Koo, S., Bryar, J. M., Page, J. H., Baden, L. R. & Marty, F. M. ( 2009; ). Diagnostic performance of the (1→3)-β-d-glucan assay for invasive fungal disease. Clin Infect Dis 49, 1650–1659.[CrossRef]
    [Google Scholar]
  10. Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., Verschakelen, J. & Boogaerts, M. ( 2002; ). Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186, 1297–1306.[CrossRef]
    [Google Scholar]
  11. Maertens, J., Theunissen, K., Verbeken, E., Lagrou, K., Verhaegen, J., Boogaerts, M. & Eldere, J. V. ( 2004; ). Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126, 852–860.[CrossRef]
    [Google Scholar]
  12. Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M. & other authors ( 2005; ). Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41, 1242–1250.[CrossRef]
    [Google Scholar]
  13. Maertens, J. A., Klont, R., Masson, C., Theunissen, K., Meersseman, W., Lagrou, K., Heinen, C., Crepin, B., Van Eldere, J. & other authors ( 2007; ). Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 44, 1329–1336.[CrossRef]
    [Google Scholar]
  14. Marr, K. A., Carter, R. A., Crippa, F., Wald, A. & Corey, L. ( 2002; ). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34, 909–917.[CrossRef]
    [Google Scholar]
  15. Marr, K. A., Balajee, S. A., McLaughlin, L., Tabouret, M., Bentsen, C. & Walsh, T. J. ( 2004; ). Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190, 641–649.[CrossRef]
    [Google Scholar]
  16. Marty, F. M., Lowry, C. M., Lempitski, S. J., Kubiak, D. W., Finkelman, M. A. & Baden, L. R. ( 2006; ). Reactivity of (1→3)-β-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 50, 3450–3453.[CrossRef]
    [Google Scholar]
  17. Mattiuzzi, G., Kantarjian, H., Odabasi, Z., Alvarado, G., Paetznick, V., Rodríguez, J., Chen, E. & Ostrosky-Zeichner, L. ( 2007; ). Diagnostic performance of serum galactomannan (GM) and β-glucan (BG) in a cohort of 395 patients (pts) with acute leukemia on antifungal prophylaxis. In Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, abstract M-578. Washington, DC: American Society for Microbiology.
  18. Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J. & Donnelly, J. P. ( 2009; ). Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9, 89–96.[CrossRef]
    [Google Scholar]
  19. Mennink-Kersten, M. A., Ruegebrink, D. & Verweij, P. E. ( 2007; ). Reactivity of bacteria with the 1,3-β-glucan assay. In Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, abstract M-568. Washington, DC: American Society for Microbiology.
  20. Nagasawa, K., Yano, T., Kitabayashi, G., Morimoto, H., Yamada, Y., Ohata, A., Usami, M. & Horiuchi, T. ( 2003; ). Experimental proof of contamination of blood components by (1→3)-β-d-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 6, 49–54.[CrossRef]
    [Google Scholar]
  21. Obayashi, T., Negishi, K., Suzuki, T. & Funata, N. ( 2008; ). Reappraisal of the serum (1→3)-β-d-glucan assay for the diagnosis of invasive fungal infections – a study based on autopsy cases from 6 years. Clin Infect Dis 46, 1864–1870.[CrossRef]
    [Google Scholar]
  22. Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H. & other authors ( 2004; ). β-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39, 199–205.[CrossRef]
    [Google Scholar]
  23. Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R. & other authors ( 2005; ). Multicenter clinical evaluation of the (1→3) β-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41, 654–659.[CrossRef]
    [Google Scholar]
  24. Pagano, L., Caira, M., Candoni, A., Offidani, M., Fianchi, L., Martino, B., Pastore, D., Picardi, M., Bonini, A. & other authors ( 2006; ). The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91, 1068–1075.
    [Google Scholar]
  25. Pazos, C., Ponton, J. & Del Palacio, A. ( 2005; ). Contribution of (1→3)-β-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43, 299–305.[CrossRef]
    [Google Scholar]
  26. Persat, F., Topenot, R., Piens, M. A., Thiebaut, A., Dannaoui, E. & Picot, S. ( 2002; ). Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses 45, 455–460.
    [Google Scholar]
  27. Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S. & Sulahian, A. ( 2008; ). Contribution of the (1→3)-β-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 46, 1009–1013.[CrossRef]
    [Google Scholar]
  28. Pickering, J. W., Sant, H. W., Bowles, C. A., Roberts, W. L. & Woods, G. L. ( 2005; ). Evaluation of a (1→3)-β-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43, 5957–5962.[CrossRef]
    [Google Scholar]
  29. Sendid, B., Poirot, J. L., Tabouret, M., Bonnin, A., Caillot, D., Camus, D. & Poulain, D. ( 2002; ). Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51, 433–442.
    [Google Scholar]
  30. Senn, L., Robinson, J. O., Schmidt, S., Knaup, M., Asahi, N., Satomura, S., Matsuura, S., Duvoisin, B., Bille, J. & other authors ( 2008; ). 1,3-β-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46, 878–885.[CrossRef]
    [Google Scholar]
  31. Usami, M., Ohata, A., Horiuchi, T., Nagasawa, K., Wakabayashi, T. & Tanaka, S. ( 2002; ). Positive (1→3)-β-d-glucan in blood components and release of (1→3)-β-d-glucan from depth-type membrane filters for blood processing. Transfusion 42, 1189–1195.[CrossRef]
    [Google Scholar]
  32. von Eiff, M., Roos, N., Schulten, R., Hesse, M., Zuhlsdorf, M. & van de Loo, J. ( 1995; ). Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62, 341–347.[CrossRef]
    [Google Scholar]
  33. Watanabe, T., Yasuoka, A., Tanuma, J., Yazaki, H., Honda, H., Tsukada, K., Honda, M., Gatanaga, H., Teruya, K. & other authors ( 2009; ). Serum (1→3) β-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 49, 1128–1131.[CrossRef]
    [Google Scholar]
  34. WHO ( 1979; ). WHO Handbook for Reporting Results of Cancer Treatment, 1st edn, pp. 15–22. Geneva, Switzerland: World Health Organization.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.019299-0
Loading
/content/journal/jmm/10.1099/jmm.0.019299-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error